Objectives and background: Oscillations in end-tidal carbon dioxide (et-CO 2 ) drive the characteristic ventilatory oscillations of periodic breathing (PB) and Cheyne-Stokes respiration (CSR) in heart failure (HF). Exogenous CO 2 administration (constant concentration, constant flow) successfully avoids apnoeas but is associated with significantly increased et-CO 2 which may contribute to sympathetic hyperactivity.
Objectives and background: Oscillations in end-tidal carbon dioxide (et-CO 2 ) drive the characteristic ventilatory oscillations of periodic breathing (PB) and Cheyne-Stokes respiration (CSR) in heart failure (HF). Exogenous CO 2 administration (constant concentration, constant flow) successfully avoids apnoeas but is associated with significantly increased et-CO 2 which may contribute to sympathetic hyperactivity.
We aimed to minimise the quantity of CO 2 delivered whilst still stabilising ventilation, by specifically targeting the hyperventilation phase, which drives down CO 2 levels. By filling in theses troughs in et-CO 2 with small doses of CO 2 , we aimed to establish whether et-CO 2 oscillations may be attenuated, stabilizing PB without significantly increasing et-CO 2 and ventilation.
Methods:
Seven heart failure patients with spontaneous daytime PB (four had apneas, EF 18.5±7.4, cardiac output 4.1±1.2 L/min) underwent dynamic CO 2 administration delivered by an automated algorithm that monitors ventilation but not CO 2 . Starting from a fixed concentration of CO 2 in a reservoir and using a custom motorized valve, CO 2 was delivered in a sinusoidal profile with the peak concentration (2%) timed to be coincident with peak ventilation for up to half the ventilatory cycle. The coefficient of variation and mean et-CO 2 and ventilation, for baseline PB, dynamic therapy and static CO2 administration (2%, constant flow throughout the ventilatory cycle) were assessed.
Overview of the delivery system
Representation of the system used to dynamically deliver CO2 to the subject.
Results: Et-CO 2 oscillations were 52% smaller (sd/mean = 0.072±0.03 untreated versus 0.041±0.023 treated CO 2 , p‹0.01) following dynamic CO 2 administration, without significantly increasing mean et-CO 2 (4.7±0.4 versus 5.0±0.3 kPa, p=0.06). This significant attenuation of end-tidal CO 2 oscillations resulted in dramatic attenuation of the ventilatory oscillations by 68% (sd/mean of ventilation from 0.43±0.19 untreated to 0.13±0.09 treated, p=0.01 but critically there was no increase in mean ventilation with dynamic administration (0.14±0.03 versus 0.16±0.05 L/s, p=0.12). Application of static CO 2 rather than dynamic CO 2 also stabilised breathing (sd/mean of ventilation 0.14±0.06 and sd/mean CO 2 0.026±0.006). However static CO 2 significantly increased end-tidal CO 2 (5.2±0.3 versus 4.7±0.4 kPa, p=0.03) and ventilation (0.20±0.07 versus 0.14±0.03 L/s, p=0.03). There was a non-significant trend toward reduced oscillations in BP (sd/mean = 0.14±0.11 versus 0.08±0.03, p=0.15when with dynamic CO 2 administration. Dynamic CO2 administration in one patient with Cheyne-Stokes respiration Example of one patient with heart failure and daytime Cheyne-Stokes respiration efficaciously treated with dynamic CO2. The delivery of 2% CO2 (peak dose) at 0° with an angle width of delivery ranging from -90° to +140° was able to abolish not only the oscillation in end-tidal CO2, but also the fluctuation in ventilation, without increasing their average values.
Conclusions:
This study demonstrates that dynamic CO 2 administration, when given at the right time, almost abolishes the oscillations in end-tidal CO 2 that drive PB. We have demonstrated a simple algorithm that can control delivery in real time, using only a ventilatory signal to guide it. Dynamic CO 2 offers an opportunity to develop therapies for PB, whilst avoiding some pitfalls of static CO 2 therapy.
